Respiratory Infection in Reptiles: A Clinical Reference for Snakes and Lizards

Bottom line

Respiratory infection in snakes and lizards is, in the majority of cases, a secondary bacterial disease driven by suboptimal husbandry. Chronically cool enclosures below the species' preferred optimal temperature zone (POTZ), incorrect humidity, poor hygiene, and crowding produce the immunosuppression that lets opportunistic gram-negative organisms — most often Aeromonas and Pseudomonas spp. — colonize the respiratory tract [1]. Effective management therefore has two inseparable arms: culture-and-sensitivity-directed antimicrobials, and correction of the underlying environment. Treating the infection while leaving the reptile in the conditions that caused it reliably fails.

What causes respiratory infection in reptiles?

Most clinical respiratory disease in captive snakes and lizards is opportunistic bacterial infection layered on a husbandry deficit. Aeromonas and Pseudomonas spp. are frequently isolated, and many respiratory infections are mixed rather than single-organism [1]. Other gram-negatives (including Klebsiella) and anaerobes appear in mixed cultures, which is precisely why empirical single-agent therapy is a poor first move.

The husbandry driver is the load-bearing concept. Reptiles are ectotherms whose innate and adaptive immune function is temperature-dependent; an animal held chronically below its POTZ mounts a blunted response, and the same cool, damp, or dirty enclosure that suppresses the host also favors bacterial proliferation. Low or incorrect humidity, inadequate ventilation, fecal contamination, and social stress all compound the effect. In turtles and lizards specifically, respiratory infection often sits on top of an underlying vitamin A deficiency, which drives squamous metaplasia of respiratory epithelium and must be corrected as part of therapy [1] — see the companion hub on reptile hypovitaminosis A.

Non-bacterial primaries also occur and should not be forgotten:

• Viral. Ferlavirus (reptilian paramyxovirus) is highly contagious and causes predominantly respiratory signs; because it initiates severe inflammation, secondary bacterial infection is common, producing nasal discharge, open-mouth breathing, caseated pus in the oral cavity, and labored breathing. Occasional CNS involvement (tremors, opisthotonos) occurs. There is no specific antiviral therapy [2]. In pythons and boas, serpentovirus (a nidovirus/coronavirus) causes pneumonia and stomatitis [2]; in one longitudinal captive-collection study clinical respiratory signs were common in infected pythons (85 of 144 snakes), and over a 28-month period infection was associated with death of 75% of infected pythons versus no uninfected pythons [3].
• Fungal. Aspergillus and Candida spp. have been isolated from pulmonary lesions in lizards and chelonians; infections typically form granulomas or plaques with respiratory distress preceding death, and reports of successful treatment of systemic mycoses in reptiles are few [4].
• Chelonian caveat. Mycoplasma is the classic cause of upper respiratory tract disease in tortoises and is slow-growing and easily missed on routine culture; this hub is snake/lizard-focused, but keep mycoplasmosis on the differential list for any chelonian and treat with tetracyclines or macrolides rather than the gram-negative-directed agents below [1].

What are the clinical signs of respiratory infection in reptiles?

The cardinal signs in snakes and lizards are open-mouth breathing, nasal or glottal discharge, and dyspnea [1]. Additional findings include audible clicking or wheezing, excess oral or tracheal mucus, forced exhalation, gaping, lethargy, anorexia, and — in snakes — a stretched or elevated head-and-neck posture adopted to ease airway obstruction. Do not conflate that positional dyspnea posture with true neurologic "stargazing," which points toward CNS disease (e.g., ferlavirus or inclusion body disease) rather than uncomplicated bacterial pneumonia. Because snakes have a simple saccular lung with limited reserve, animals frequently present already dyspneic and hypoxemic; caseated purulent material in the glottis or oral cavity, when present, suggests either advanced bacterial disease or a viral primary such as ferlavirus [2]. Cross-check the oral cavity for concurrent infectious stomatitis / mouth rot, which shares gram-negative etiology and often coexists.

How is respiratory infection diagnosed in reptiles?

Culture and sensitivity from a lower-airway sample is the diagnostic standard, and it should drive antibiotic selection rather than empirical choice [1]. Given the mixed, opportunistic, and multidrug-resistant nature of reptile gram-negatives, guessing at an agent is unreliable.

A practical work-up:

• Tracheal / lung wash for culture, sensitivity, and cytology. A sterile transtracheal or endoscopic wash yields the sample that matters; submit for aerobic and anaerobic culture with sensitivities plus cytology. This is the single highest-value test and the reason to avoid committing to an antibiotic before sampling.
• Radiography (dorsoventral and horizontal-beam). Confirms pulmonary involvement and consolidation; horizontal-beam views are particularly useful in snakes and chelonians for fluid lines.
• Endoscopy / pulmonoscopy. Direct visualization and targeted lung biopsy for histology and culture, especially where granulomatous (fungal) disease is suspected [4].
• PCR for viral primaries. Serpentovirus is detected by PCR on oral/choanal swabs [3]; nidovirus can also be found by PCR of oral swabs and tracheal washes, and ferlavirus by PCR alongside hemagglutination-inhibition serology [2]. Run these whenever a collection is affected or bacterial therapy underperforms.
• Hematology and biochemistry to gauge systemic impact and guide supportive care.

How is respiratory infection treated in reptiles?

Treatment is culture-directed systemic antimicrobials plus aggressive husbandry correction plus supportive care. Because most infections are gram-negative, broad-spectrum agents used pending sensitivities include amikacin, enrofloxacin, ceftazidime, and piperacillin [7]; narrow to the sensitivity result as soon as it returns.

Systemic antibiotics (species-specific, from named reptile sources).

• Ceftazidime is a well-supported first-line gram-negative cephalosporin in snakes. The original squamate pharmacokinetic work dosed 20 mg/kg IM, reached peak plasma concentrations up to 70.5 µg/mL at 1–8 hours, maintained therapeutic levels for at least 96 hours, and — in five snake species held at 30 °C (86 °F) — showed a half-life of 24 hours, supporting a 72-hour dosing interval [5]. More recent chelonian data reinforce the long interval: subcutaneous ceftazidime at 20 and 40 mg/kg produced theoretically therapeutic plasma concentrations for at least 120 hours in red-eared sliders (Trachemys scripta elegans), a species-specific figure that should not be extrapolated uncritically to squamates [6].
• Aminoglycosides (amikacin) and fluoroquinolones (enrofloxacin) are commonly used gram-negative options [7], but note the off-label status of essentially all reptile antibiotic use, the nephrotoxic risk of aminoglycosides (mandating adequate hydration and, where possible, therapeutic monitoring), and enrofloxacin's tendency to cause tissue irritation and discoloration at injection sites.
• Temperature is a dosing variable, not a comfort measure. Reptiles with respiratory infection should be maintained at the mid-to-upper range of their POTZ; increased temperature stimulates the immune response, helps mobilize respiratory secretions, and ensures proper drug metabolism for effective treatment [1]. Antibiotic half-life is temperature-dependent, so an animal kept too cool is both immunosuppressed and under-dosed.

Nebulization delivers drug directly to the airway and reduces systemic exposure. A described reptile protocol nebulizes amikacin 50 mg (1.0 mL) mixed with 9.0 mL sterile saline, repeated every 12 hours; when nebulizing an aminoglycoside, avoid giving the same drug parenterally to prevent cumulative overdose [7]. Mucolytics such as N-acetylcysteine have been nebulized to loosen respiratory secretions, though evidence for safety and efficacy in reptiles remains limited and caution is advised [1].

Antifungals, when culture/histology confirm mycotic pneumonia, include amphotericin B, itraconazole, fluconazole, and voriconazole; nystatin has been used for candidiasis in large snakes at 100,000 U PO for 10 days, and amphotericin B has been delivered by intrapneumonic catheter — but prognosis for systemic mycoses is guarded and documented successes are few [4].

Supportive care and husbandry correction (the non-negotiable arm). Provide fluid therapy for dehydrated or anorexic patients, assisted feeding as needed, and coupage/nebulization to clear secretions. Simultaneously fix the environment that caused the disease: raise the ambient and basking gradient into the correct POTZ, correct humidity to the species' requirement, improve ventilation, and impose strict enclosure hygiene. Correct concurrent nutritional deficits (vitamin A in lizards and chelonians) [1]. For viral outbreaks, isolate affected animals and enforce quarantine and biosecurity, since ferlavirus and serpentovirus spread through respiratory secretions and direct contact within a collection [2][3].

What is the prognosis for respiratory infection in reptiles?

Prognosis hinges on chronicity, the primary agent, and whether husbandry is corrected. Early, culture-directed bacterial cases caught before pulmonary consolidation carry a fair-to-good prognosis when temperature and environment are simultaneously fixed; snakes given ceftazidime in the original squamate study showed a rapid and obvious clinical response [5]. Advanced consolidated bacterial pneumonia, fungal disease (few documented cures) [4], and confirmed serpentovirus in pythons (up to 75% mortality among infected pythons over 28 months in one collection) [3] carry a substantially worse outlook. The recurring clinical failure is treating the infection while leaving the reptile in the sub-POTZ, low-hygiene enclosure that produced it — durable resolution requires correcting both.

Frequently Asked Questions

Why is culture and sensitivity preferred over empirical antibiotics in reptile respiratory infection?

Because reptile respiratory infections are predominantly gram-negative, frequently mixed, and commonly involve multidrug-resistant organisms, the Merck Veterinary Manual (professional/exotic edition) frames culture and susceptibility testing as the standard that should determine antimicrobial selection. Aeromonas and Pseudomonas spp. are frequently isolated and many infections are mixed, so an empirical single agent is an unreliable first move; a tracheal or lung wash submitted for culture, sensitivity, and cytology gives the sample that should drive therapy.

What is the ceftazidime dose for a snake with respiratory infection?

The original squamate pharmacokinetic study (Lawrence, in snakes) used ceftazidime 20 mg/kg IM, reported peak plasma concentrations up to 70.5 µg/mL at 1–8 hours, therapeutic levels maintained for at least 96 hours, and a 24-hour half-life in five snake species held at 30 °C, supporting a 72-hour dosing interval. Newer AJVR data in red-eared sliders show 20 and 40 mg/kg SC hold theoretically therapeutic concentrations for at least 120 hours, but that is a chelonian figure and should not be extrapolated uncritically to squamates. All reptile antibiotic use is off-label.

Why does raising the temperature matter so much in treatment?

Per the Merck Veterinary Manual (professional/exotic edition), reptiles with respiratory infection should be held at the mid-to-upper range of their preferred optimal temperature zone because increased temperature stimulates the immune response, helps mobilize respiratory secretions, and ensures proper drug metabolism for effective treatment. As an ectotherm, a reptile kept below its POTZ is both immunosuppressed and effectively under-dosed since antibiotic half-life is temperature-dependent.

How is nebulization dosed in reptiles?

A described reptile aerosolization protocol (Raiti, ARAV proceedings) nebulizes amikacin 50 mg (1.0 mL) mixed with 9.0 mL sterile saline, repeated every 12 hours, delivering drug directly to the airway. When nebulizing an aminoglycoside, avoid administering the same drug parenterally to prevent cumulative overdose. Broad-spectrum agents suited to the gram-negative etiology include amikacin, enrofloxacin, ceftazidime, and piperacillin.

When should I suspect a viral rather than bacterial cause?

The Merck Veterinary Manual (professional/exotic edition) notes ferlavirus (reptilian paramyxovirus) causes predominantly respiratory signs with common secondary bacterial infection, producing nasal discharge, open-mouth breathing, caseated oral pus, and labored breathing, sometimes with tremors or opisthotonos. Suspect a viral primary — ferlavirus, or serpentovirus/nidovirus in pythons and boas — when multiple animals in a collection are affected, when caseous oral lesions accompany respiratory signs, or when appropriate antibiotics underperform; confirm by PCR.

How is serpentovirus (nidovirus) diagnosed and how dangerous is it?

Hoon-Hanks and colleagues (Frontiers in Veterinary Science, 2019) detected serpentovirus by PCR on oral/choanal swabs and reported clinical respiratory signs were common in infected pythons (85 of 144 snakes), with infection associated with death of 75% of infected pythons versus no uninfected pythons over a 28-month period in one collection. Infection was persistent with no observed viral clearance, so PCR screening and strict quarantine are central to protecting a python collection.

Do lizards with respiratory infection need anything beyond antibiotics?

Yes. The Merck Veterinary Manual (professional/exotic edition) states that turtles and lizards with respiratory infections often have an underlying vitamin A deficiency requiring dietary correction, because hypovitaminosis A drives squamous metaplasia of respiratory epithelium that predisposes to and perpetuates infection. Correcting the deficiency, alongside temperature and hygiene, is part of definitive therapy rather than an optional add-on.

What antifungals are used if the pneumonia is mycotic?

The Merck Veterinary Manual (professional/exotic edition) lists amphotericin B, itraconazole, fluconazole, and voriconazole for deep fungal respiratory infection, notes nystatin has been used for candidiasis in large snakes at 100,000 U PO for 10 days, and reports amphotericin B has been delivered by intrapneumonic catheter. Because Aspergillus and Candida infections form granulomas or plaques and documented successful treatments of systemic reptile mycoses are few, the prognosis for confirmed fungal pneumonia is guarded and diagnosis should rest on histology plus fungal identification.